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Abstract
Objective: Thrombotic diseases are caused by genetic and environmental factors. There are a number of well-characterized 
genetic defects that lead to increased risk of thrombosis. Results from previous studies have indicated that FXII is involved 
in the pathogenesis of thrombophilic diseases. However, the results in this regard are highly controversial. One of the most 
important determinants of Plasma FXII level is 46CgT polymorphism in the FXII gene. In the present study, the risk of 
thrombophilic diseases related to this polymorphism was investigated in a case-control study. 
Material and Methods: One hundred and sixty subjects were studied: 120 patients diagnosed with thrombophilia (96 
venous thromboembolism, 24 arterial thrombosis), and 40 age-gender-matched controls. For each subject, FXII activity 
level was measured by a one-step clotting assay with FXII-deficient plasma, and 46CaT polymorphism was genotyped 
using a restriction fragment length polymorphism (RFLP) method. 
Results: In this study, the previous observation that individuals with different genotypes for the 46 CaT polymorphism show 
significant differences in FXII activity levels was confirmed. Most importantly, FXII activity 68% was associated with an 
increased risk of venous thrombosis with an adjusted odds ratio (OR) of 4.7 (95% confidence interval [CI]: 1.03-21.1, p=0.04). 
However, it was not a risk factor for arterial thrombosis with adjusted OR of 5 (95% CI: 0.91-27.1, p=0.09). In CT and TT 
genotype, the adjusted ORs were 2 (95% CI: 0.9-4.4, p=0.11) and 2.3 (95% CI: 0.45-11, p=0.48), respectively, for patients 
with venous thrombosis compared with the controls. Similarly, the adjusted ORs in arterial thrombosis were 1.2 (95% 
CI: 0.4-3.6, p=0.76) for CT and 1.8 (95% CI: 0.2-14.9, p=0.59) for TT genotype. Thus, we did not find any association of the 
mutated T allele in the heterozygous or homozygous state with an increased risk of venous or arterial thrombosis. 
Conclusion: Lower FXII activity is not a risk factor; rather, it simply represents a risk marker for thrombosis.
(Turk J Hematol 2010; 27: 15-9)
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Özet
Amaç: Trombotik hastalÕklar genetik ve çevresel faktörlerden kaynaklanmaktadÕr. Yüksek tromboz riskine yol açan çok 
sayÕda iyi karakterize edilmiý genetik defekt mevcuttur. Önceki çalÕýmalardan elde edilen sonuçlarda, FXII’nin trombofilik 
hastalÕklarÕn patojenezinde yer aldÕúÕ gösterilmiýtir. Bununla birlikte, sonuçlar bu bakÕmdan oldukça tartÕýmalÕdÕr. FXII genin-
deki 46CaT polimorfizmi FXII aktivite düzeylerini etkileyen faktörlerden birisidir. Mevcut çalÕýma kapsamÕnda, bu polimor-
fizm ile iliýkili trombofilik hastalÕklar riski bir vaka kontrol çalÕýmasÕnda araýtÕrÕlmÕýtÕr. Introduction
Thrombosis is a common cause of morbidity and mortality 
in industrialized nations. Both venous and arterial thrombosis 
can be life-threatening events, and both are of great public 
health importance [1]. Risk factors for thrombosis can be either 
genetic or acquired. 
Current research on complex diseases, such as ischemic 
stroke (IS), now focuses on identifying genetic variants that 
increase the susceptibility to thrombotic disorders [2-4]. 
Among the clotting factors studied, factor XII (FXII) levels exhib-
ited one of the highest heritabilities (67%) and a significant 
positive genetic correlation with thrombotic disease [5], indicat-
ing that some of the polymorphisms and mutations that influ-
ence variation in this physiological risk factor also influence 
liability to thrombosis.
Plasma coagulation FXII (Hageman factor) is an 80-KDa 
serine protease with an average plasma concentration of 30 
g/ml. Contact of FXII with negatively charged surfaces leads 
to proteolytic cleavage and activation of the FXII molecule. The 
generated FXIIa can initiate activation of factor XI and also 
seems to participate in the conversion of plasminogen to plas-
min [6,7]. While in vitro, FXII plays a central role in the initiation 
of coagulation and fibrinolysis, the physiological function of FXII 
is still under discussion. 
Factor XII gene spans a total of 12kb and is composed of 
14 exons and 13 introns. It is reported to be located at 5q33-
qter in the human chromosome [8]. The concentration of 
plasma FXII has been known to vary widely between individuals 
and races [9]. Recently, a frequent CJT promoter polymor-
phism at nucleotide 46 of the FXII gene has been identified in 
which the T allele creates a novel methionine-initiating codon, 
which results in a lower translation efficiency and decrease in 
FXII plasma levels [10]. 
Here, the relation of plasma FXII activity and a common 
C46T polymorphism of the FXII gene with the risk of throm-
botic disease was explored in a case-control study. The iden-
tification of these relations may help to elucidate the mecha-
nism underlying the risk of common thrombosis and therefore 
may suggest preventive strategies to reduce thrombosis-
related morbidity and mortality. 
Materials and Methods 
The study group consisted of 120 patients (65 males, 
54.2%; 55 females, 45.8%) diagnosed with a thrombophilic 
disorder based on clinicians’ decision and 40 age-gender-
matched control subjects. The patient group consisted of 96 
venous thromboembolism (VTE) subjects (24 pulmonary embo-
lism; 36 cerebral venous thrombosis; 36 deep vein thrombosis) 
and 24 subjects with arterial thrombosis [myocardial infarction 
[MI]). Patients were recruited from the hemophilia center in Iran. 
The patients were aged 21 to 64 years (41.9±10.8), with 73 
(60.8%) individuals aged <45 and 47 (39.2%) aged >45 years. 
The patients who had no previous diagnosis of malignant dis-
ease or thrombophlebitis, with no history of diabetes mellitus 
or recent surgery, with normal renal and hepatic function, and 
who were not taking any drugs known to affect the coagulation 
system were included in the study protocol. Moreover, all of 
the patients were screened for FVL (factor V Leiden), pro-
thrombin G20210A mutation, and protein C and S deficiency, 
and only patients with negative screening were included in the 
study. Control subjects were friends and spouses of patients 
who were recruited at the same time as the patients. They 
were included only if they had no personal history of thrombo-
embolic disease, including venous and arterial thrombosis, 
cirrhosis, nephritic syndrome, or cancer. The control group 
was matched for age (20 to 60; mean 41.2±10.8; with 27 indi-
viduals (67.5%) aged <45 and 13 (32.5%) aged >45 years), 
and sex (22 males, 18 females). All individuals provided their 
informed consent to take part in the study, and the study was 
approved by the local ethics committee.
For FXII activity determination, a one-step clotting assay 
with FXII-deficient plasma (Technoclone, Austria) and the acti-
vated partial thromboplastin time (aPTT) reagent (Technoclone, 
Austria) were used on a Sysmex Ca-1500 coagulometer.
For genetic analysis, DNA was extracted by the phenol-
chloroform method from blood cells. Then, polymerase chain 
reaction (PCR) amplification of exon 1 of the FXII gene was 
performed using the following primer pair to produce a frag-
ment of 142 bp. The forward primer was 5´-GAT AGG CAG 
CTG GAC CAA CG-3´; the reverse primer was 5´-TGA TAG 
CGA CCC CCC AGA AC-3´. The sequence surrounding the 
Yöntem ve Gereçler: Yüz altmÕý denek incelenmiýtir: 120 hastaya trombofili (96’sÕ tromboembolizm, 24’ü arteriyel tromboz) 
tanÕsÕ konmuý olup 40 hasta yaý ve cinsiyet açÕsÕndan eýleýtirilmiýtir. Her bir denek için, FXII aktivite düzeyi, FXII’den yoksun 
plazma ile tek adÕmlÕ pÕhtÕlaýma testi kullanarak ölçülmüý ve 46CaT polimorfizmi, (RFLP) yöntemi ile genotiplenmiýtir. 
Bulgular: 46 CaT polimorfizmi için farklÕ genotipleri olan bireylerin FXII aktivite düzeylerinde anlamlÕ farklÕlÕklar sergilediúine dair 
önceki gözlem, bu çalÕýmada doúrulanmÕýtÕr. Daha da önemlisi, %68 olan FXII aktivitesi, 4.7 ayarlanmÕý risk oranÕ (OR) ile venöz 
tromboza yönelik yüksek risk ile iliýkilendirilmiýtir (%95 güven aralÕúÕ [CI]: 1.03-21.1, p=0.04). Ancak bu, 5 ayarlanmÕý OR ile arte-
riyel tromboza yönelik bir risk faktörü deúildir (%95 CI: 0.91-27.1, p=0.09). Ct ve TT genotipte, ayarlanmÕý OR deúerleri, kont-
rollere kÕyasla venöz trombozlu hastalar için sÕrasÕyla 2 (%95 CI: 0.9-4.4, p=0.11) ve 2.3 (%95 CI: 0.45-11, p=0.48) idi. Benzer 
ýekilde, arteriyel trombozda ayarlanmÕý OR deúerleri CT genotip için 1.2 (%95 CI: 0.4 - 3.6, p=0.76) ve TT genotip için 1.8 (%95 
CI: 0.2-14.9, p=0.59) idi. Böylelikle, heterozigot veya homozigot halde mutasyona uúramÕý T aleli ile venöz ya da arteriyel trom-
boza iliýkin yüksek risk arasÕnda herhangi bir iliýki tespit edilmemiýtir. 
Sonuç: Düýük FXII aktivitesi bir risk faktörü olmamakla birlikte, yalnÕzca tromboza yönelik bir risk göstergesini temsil etmektedir.   
(Turk J Hematol 2010; 27: 15-9)
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restriction enzyme (Fermentas, Russia) site. The C46 wild type 
sequence (GACGCC) contains this BsaHI site, which is abol-
ished in the T46 rare variant (GATGCC). In the presence of the 
C allele, BsaHI digestion yields fragments of 116 and 26 bp, 
whereas in the presence of the T allele, digestion does not 
occur.
After overnight incubation of the PCR product with BsaHI 
restriction enzyme in 37°C, electrophoresis on 8% TBE-PAG 
(tris borate EDTA-polyacrylamide gel) for 90 min at 150V, and 
staining with ethidium-bromide for 10 min, bands were visual-
ized on an UV transilluminator and photographed using a 
Polaroid land camera.
Statistical analyses were performed using SPSS software 
version 14.0, and values of p<0.05 were considered signifi-
cant. Odds ratio (OR) was also calculated as relative risk for 
thrombosis. 
Results
Of 40 tested healthy volunteers, 26 (65%) carried FXII 
46C genotype, 12 (30%) were heterozygous, and 2 (5%) 
were homozygous for FXII 46T genotype. The allele frequen-
cies of 46C and 46T were estimated as 0.8 and 0.2, respec-
tively.
The FXII activity levels, analyzed as a function of the 46 
CJT polymorphism, showed statistically significant differ-
ences between the different genotypes (p=0.002). Genotype 
T/T showed the lowest levels of FXII activity (58±11.3) com-
pared with the levels of the other genotypes (C/C genotype: 
123±30.3 and C/T genotype: 97.3±23).
In both the patient and control groups, the CC genotype 
had the highest frequency, and TT the lowest. CC frequency 
was higher in controls (65%) than patients with VTE and MI 
(48% and 58.3%, respectively), but CT and TT frequencies 
were higher in patients with VTE (44% and 8%, respectively) 
and MI (33.3% and 8.3%, respectively) than controls (30% 
and 5%, respectively). The C/T allele frequency in patients 
with VTE and MI were 70/30 and 75/25 compared with 
80/20 in controls. Therefore, the risk of thrombosis associ-
ated with the genotype CT and TT was studied. CC geno-
type was considered as a reference group, and the OR of 
thrombosis associated with the 46 CJT polymorphism for 
genotypes CT  and TT  was calculated in VTE patients 
(Table 1) and MI patients (Table 2) compared with the con-
trols. The results suggest that neither genotype CT nor TT is 
a risk factor for arterial or venous thrombosis.
In both the patient and control groups, CC demonstrated 
the highest FXII activity level and TT the lowest FXII activity 
levels. The mean values of plasma FXII activity levels were 
112±32.2 in controls compared with 87±23 in VTE patients 
and 84±21 in MI patients. There were statistically significant 
differences in mean values of FXII activity levels between 
patients and controls (p=0.001). Thus, it was speculated 
that decreased FXII activity is a risk factor for thrombosis. 
Consequently, OR was calculated as a risk for thrombosis. 
Levels lower than the 10th percentile (lower than 68%) were 
used as a cut-off, and FXII activity >68% was considered as 
a reference group. The risk of thrombosis associated with 
FXII activity levels in VTE and MI patients is shown in Table 
1 and Table 2, respectively. The results suggest that FXII 
activity  68% is an independent risk factor for venous 
thrombosis. However, it is not a risk factor for arterial throm-
bosis.
Table 1. Risk of VTE associated with CT, TT genotype and FXII activity
   Patients  Controls  OR  95% CI  P
CC  46 (48%)  26 (65%)  1 *  ----  ----
CT  42 (44%)  12 (30%)  2  0.9-4.4  0.11
TT  8 (8%)  2 (5%)  2.3  0.45-11  0.48
FXII activity >68%   77 (80.2%)  38 (95%)  1# ----  ----
FXII activity 68%   19 (19.8%)  2 (5%)  4.7  1.03-21.1  0.04
* Reference group: subjects with CC genotype, # Reference group: subjects with FXII activity >68, Reference range for FXII activity: 50% - 150% 
Table 2. Risk of MI associated with CT, TT genotype and FXII activity
   Patients  Controls  OR  95% CI  P
   (N=96)  (N=40)
CC 14  (58.3%)  26  (65%)  1*  ----  ----
CT  8 (33.3%)  12 (30%)  1.2  0.4-3.6  0.76
TT  2 (8.3%)  2 (5%)  1.8  0.2-14.9  0.59
FXII activity >68%   19 (79.2%)  38 (95%)  1# ----  ----
FXII activity 68%   5 (20.8%)  2 (5%)  5  0.91-27.1  0.09
* Reference group: subjects with CC genotype, #Reference group: subjects with FXII activity >68, Reference range for FXII activity: 50%-150% 
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It is well-known that plasma level of FXII is variable among 
different individuals and races due to genetic and environmen-
tal factors. Various factors such as estrogen, interleukin 6 [11], 
specific lipoprotein particles [12] and a dysfunctional endothe-
lium [13] were shown to have a significant influence on FXII 
levels. This study confirms and extends the previous observa-
tion that the 46CJT polymorphism in the FXII promoter region 
correlates with lower FXII plasma activity. 
In this study, the allele frequency of 46 C/T was 0.8/0.2 in 
a small Iranian population (allele number=80), which is exactly 
the same as the allele frequency found by Kanaji [10] in 
Caucasians (allele number=40). Further, genotype frequency in 
that study corresponded to the genotype frequency in Austrians 
(who are representative of the Middle European population) 
reported by Endler et al. [14] in 100 healthy Austrian newborns 
and those in the United Kingdom found by Kohler et al. [15]. 
Conversely, the allele frequency of 46 C/T in Orientals has 
been shown to be 0.27/0.73 [10], which contradicts our 
results. This can be explained by racial and geographical differ-
ences.
It has been reported that the plasma levels of FXII in 
Orientals (125.4±56.3) are lower than in Caucasians (150±30.3) 
because of the differences in allele frequency of 46C/T in the 
FXII gene between the two races [10]. Although in the present 
study the allele frequency of 46C/T was exactly the same as in 
Caucasians, the level of plasma FXII activity in this study 
(112±32.2) was lower than in Caucasians. It may be because 
of the low patient number in both studies. Furthermore, 
although the C46T polymorphism in the FXII gene is an impor-
tant determiner of plasma FXII level, it is not the only effective 
factor. As previously mentioned, there are other factors that 
have a significant influence on FXII levels. Thus, further large 
scale studies considering the other effective factors on FXII 
levels may be needed to elucidate these differences.
There is controversy over the clinical significance of FXII 
deficiency because most of subjects with complete deficiency 
of FXII have no clinical manifestations. Some authors consid-
ered low FXII levels to be associated with an increased risk for 
venous [1,16,17] as well as arterial thromboembolism [18-20], 
while other studies have reported increased FXII activity in 
people with acute coronary syndromes [21,22]. In some stud-
ies, no effect of FXII levels on thrombosis was observed 
[13,23,24]. Furthermore, there are conflicting results about the 
effect of polymorphism 46CJT in the FXII gene on thrombotic 
diseases. Previous genetic association studies showed that 
genotype TT increases significantly the risk for ischemic stroke 
[25], acute coronary artery disease [26] and cerebral venous 
thrombosis [27]. Conversely, there are also studies that either 
do not detect a genetic association between this genotype and 
cardiovascular risk [28] or alternatively report an association 
between the C/C genotype and thrombosis risk [29].
Although in this study, FXII activity 68% was associated 
with an increased risk of VTE, there was no association 
between FXII activity 68% and MI risk. Moreover, no asso-
ciation of the mutated T allele in the heterozygous or homo-
zygous state with an increased risk of VTE and MI was 
found. Therefore, it was speculated that reduced FXII activ-
ity is not the cause of thrombosis, but the result of it [30],for 
the following reason: Previous studies [10,14] and this study 
showed that the substitution of T allele at nucleotide 46 in 
the FXII gene reduces FXII activity because the 46T allele 
creates a novel methionine-initiating codon that reduces the 
translation efficiency of FXII. As a result, the FXII 46CJT 
polymorphism is not merely a marker, but rather a strong 
determinant of plasma FXII levels. Notably, despite the 
importance of the FXII genotype on FXII levels, the studies 
by Bach et al. [20], Athanasiadis et al. [28] these results 
study did not observe an association between the FXII 
46T/T genotype and thrombosis. This would suggest that 
lower FXII activity is not a risk factor; rather, it simply repre-
sents a risk marker [30]. Endler et al. [31] demonstrated that 
with decreasing FXII activity, the hazard ratio for all-cause 
mortality and death as a result of ischemic heart disease 
gradually increased in an almost linear manner. However, 
mortality was not increased in individuals who had FXII 
activity that was lower than 10% of normal. While this 
appears paradoxical, the suggested reason is that the linear 
association between low FXII activity and mortality may sim-
ply reflect the progression of atherosclerosis and inflamma-
tion, and that individuals with very low FXII activity may have 
mutations that cause FXII deficiency but do not alter their 
overall survival [30].
Furthermore, FXII is a plasma protein that activates both 
coagulation and fibrinolysis. The level of plasma FXII is sug-
gested to be reduced as a consequence of activation of both 
coagulation and fibrinolysis upon thrombus formation [30].
According to our results, FXII activity is decreased as a 
result of thrombosis in both arterial and venous thrombosis. 
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